Showing results (71-80 of 120) with videos related to
Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.European Journal of Cancer & Clinical Oncology|May 1, 1986
5-Ethyl-2'-deoxyuridine: an explanation for its lack of cytotoxic action in vivoA Jeney, S E Barrie, G A Taylor, et al.British Journal of Cancer|September 1, 1991
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancerJ L Mansi, A de Graeff, D R Newell, et al.European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Cisplatin pharmacokinetics in children with cancerB Peng, M W English, A V Boddy, et al.Cancer Research|December 15, 1988
Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cellsD C Blakey, D N Skilleter, R J Price, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalationB J Foster, D R Newell, M A Graham, et al.European Journal of Cancer & Clinical Oncology|September 1, 1987
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatinD R Newell, Z H Siddik, L A Gumbrell, et al.British Journal of Cancer|February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277B J Foster, D R Newell, J Carmichael, et al.Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1996
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parametersV Mummaneni, S Kaul, L N Igwemezie, et al.Pageof 12